We need clinical trials to….
1. Determine what is the most simple, inexpensive, and rapid test of platelet function and/or metabolism genotyping that best predicts clinical outcomes of
antiplatelet therapy for specific patient subgroups? AND STICK TO IT….results in trials discussed seem to vary by assay!
2. Determine if individual outcomes are affected when treatment is
changed in response to the testing results. i.e. what is our “threshold” or “cutoff” values
3. What the benefit of supplementary treatment with an agent having a different mechanism of action in patients with known hypo-response to a given antiplatelet agent?
4. With emerging agents, is any of this ultimately going to matter?
Adapted from H. Aboul-Enein, Benha Faculty of Medicine
HOW DO WE MOVE FORWARD?